ReachMD

Episodes 1-11 of 11

• • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  • 

    

    Charles P. Vega, MD

    Peer

  2

  

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credits

• • 

    

    Eugene E. Wright, Jr., MD

    Peer

  • 

    

    Jolanta Małyszko, MD, PhD

    Peer

  • 

    

    María José Soler, MD, PhD

    Peer

  6

  

  RestartResume

  Nonsteroidal MRAs: Latest Evidence of Cardiorenal Protection in CKD and T2D

  Nonsteroidal MRAs: Latest Evidence of Cardiorenal Protection in CKD and T2D

  0.25 credits

• • 

    

    Michael Miller, MD, FACC, FAHA, FNLA

    Peer

  • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  • 

    

    Aruna Pradhan, MD, MPH

    Peer

  • 

    

    James A. Underberg, MD

    Peer

  8

  

  RestartResume

  Adopting the New Therapeutic “Lineup” to Manage ASCVD - East

  Adopting the New Therapeutic “Lineup” to Manage ASCVD - East

  3.50 credits

• • 

    

    Josep Comin-Colet, MD, PhD

    Peer

  8

  

  RestartResume

  Beyond Anemia: Addressing Iron Deficiency in Patients with Heart Failure

  Beyond Anemia: Addressing Iron Deficiency in Patients with Heart Failure

  0.25 credits

• • 

    

    Javed Butler, MD, MBA, MPH

    Peer

  • 

    

    Shelley Zieroth, MD

    Peer

  9

  

  RestartResume

  High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?

  High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?

  0.25 credits

• • 

    

    Peter Libby, MD

    Peer

  • 

    

    Lawrence A. Leiter, MD

    Peer

  • 

    

    Prof. Kausik Ray, MBChB, MD, MPhil

    Peer

  6

  

  RestartResume

  Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

  Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction

  0.25 credits

• • 

    

    Robert J. Chilton, DO

    Peer

  • 

    

    John R. Nelson, MD, FACC, FNLA, FASNC

    Peer

  6

  

  RestartResume

  Clinicians' Update on Omega-3s in ASCVD Risk Reduction  

  Clinicians' Update on Omega-3s in ASCVD Risk Reduction  

  1.00 credits

• • 

    

    Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP

    Peer

  • 

    

    Karol Watson, MD, PhD

    Peer

  10

  

  RestartResume

  A Closer Look at Women, Atherosclerosis, and Lipids: What Is Different? 

  A Closer Look at Women, Atherosclerosis, and Lipids: What Is Different? 

  0.75 credits

• • 

    

    Joseph Saseen, PharmD, BCPS, BCACP, CLS

    Peer

  • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  5

  

  RestartResume

  Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?

  Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?

  0.25 credits

• • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  • 

    

    Leslie Cho, MD

    Peer

  10

  

  RestartResume

  Clinician’s Update on Omega-3s in ASCVD Risk Reduction

  Clinician’s Update on Omega-3s in ASCVD Risk Reduction

  0.25 credits

• • 

    

    Paul W. Armstrong, MD

    Peer

  • 

    

    Justin Ezekowitz, MD, MBBCh, MSc

    Peer

  5

  

  RestartResume

  Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness

  Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness

  0.25 credits